Anal Squamous Cell Carcinoma Clinical Trial
Official title:
Feasibility Study of Adaptive Radiotherapy for the Treatment of Locally-Advanced Anal Squamous Cell Carcinoma
This is a 20 patient pilot study to examine the feasibility of dose-adapted radiation therapy for the treatment of locally advanced anal squamous cell cancer. The tumor and a patient's anatomy may change during radiation treatment and daily adaption of the radiation plan (i.e., a new daily plan based on the anatomy of the day) may help to maximize the dose to the tumor and minimize the radiation dose to the normal surrounding organs.
The standard treatment for Human Papilloma Virus (HPV)-positive locally advanced anal cancer (described as a tumor that is greater than 4 cm in size, or with positive lymph nodes) is 54 Gy of radiation treatment to the anal canal and primary tumor planning total volume (PTV), 50.4-54 Gy to positive nodal PTV and 45 Gy to elective lymph node PTV with 5-fluorouracil (5-FU) and mitomycin-C chemotherapy administered at the same time as radiation in 30 fraction (treatments) delivery. During the six week course of radiotherapy, there is often a notable decrease in volume of the tumor (both primary and regional nodes), as early as one week into treatment, detected on weekly on-board Cone Beam Computed Tomography (CBCT), which is a scan done on the treatment machine while patients receive radiation to ensure that the tumor is being treated and normal tissue is not. However, CT simulation (a CT scan used to plan radiation treatment) and re-planning of the treatment to account for the tumor shrinkage are not routinely performed due to time, patient inconvenience and staffing resources. As such, daily adaptive radiation, which can generate a new CT-based plan using the anatomy of the day, may be a time efficient method to both plan and treat the patient. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05060471 -
PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
|
Phase 2 | |
| Recruiting |
NCT06050707 -
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
|
Phase 2 | |
| Completed |
NCT04616196 -
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01285778 -
Vectibix for the Treatment of Anal Cancer
|
Phase 2 | |
| Terminated |
NCT04596033 -
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
|
Phase 1 | |
| Recruiting |
NCT05374252 -
Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
|
Phase 3 | |
| Completed |
NCT01807546 -
Oral Rigosertib for Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05328765 -
A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection
|
||
| Completed |
NCT05130073 -
4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer
|
||
| Recruiting |
NCT05438836 -
Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
|
||
| Terminated |
NCT02407561 -
Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays
|
N/A | |
| Completed |
NCT01115790 -
A Phase 1 Study in Participants With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT04929028 -
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02560298 -
Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
|
Phase 2 | |
| Withdrawn |
NCT05582031 -
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
|
Phase 2 | |
| Active, not recruiting |
NCT02437851 -
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
|
Phase 2 |